DRACHMAN JONATHAN G
Known title: President and CEOCIK: 0001588467
DRACHMAN JONATHAN G's purchase track record
DRACHMAN JONATHAN G has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/24/2021 | NGNE | $934K | -12.8% | -56.7% | -4.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NGNE | ▲ Buy | Open Market | 25,000 | $161K | 8/25/2021 | View on chart |
| NGNE | ▲ Buy | Open Market | 25,000 | $161K | 8/25/2021 | View on chart |
| NGNE | ▲ Buy | Open Market | 100,000 | $611K | 8/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Neurogene Announces Inducement Grants Under Nasdaq Rules
Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.
Neurogene Announces Inducement Grants Under Nasdaq Rules. Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.